These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29721072)

  • 1. Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21).
    Lu L; Wen Y; Yao Y; Chen F; Wang G; Wu F; Wu J; Narayanan P; Redell M; Mo Q; Song Y
    Theranostics; 2018; 8(8):2189-2201. PubMed ID: 29721072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
    Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
    Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
    Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
    Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
    Da Silva N; Meyer-Monard S; Menot ML; Parrado A; Lebel A; Balitrand N; Fenaux P; Micléa JM; Rousselot P; Degos L; Dombret H; Chomienne C
    Hematol J; 2000; 1(5):316-28. PubMed ID: 11920209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative effects of GM-CSF signaling in a murine model of t(8;21)-induced leukemia.
    Matsuura S; Yan M; Lo MC; Ahn EY; Weng S; Dangoor D; Matin M; Higashi T; Feng GS; Zhang DE
    Blood; 2012 Mar; 119(13):3155-63. PubMed ID: 22223820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
    DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
    Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted-frizzled related protein 1 is a transcriptional repression target of the t(8;21) fusion protein in acute myeloid leukemia.
    Cheng CK; Li L; Cheng SH; Ng K; Chan NP; Ip RK; Wong RS; Shing MM; Li CK; Ng MH
    Blood; 2011 Dec; 118(25):6638-48. PubMed ID: 22031861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with A t(8;21) chromosome translocation.
    Miyoshi H; Ohki M; Nakagawa T; Honma Y
    Leuk Res; 1997 Jan; 21(1):45-50. PubMed ID: 9029185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
    Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
    Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.
    Zhen T; Wu CF; Liu P; Wu HY; Zhou GB; Lu Y; Liu JX; Liang Y; Li KK; Wang YY; Xie YY; He MM; Cao HM; Zhang WN; Chen LM; Petrie K; Chen SJ; Chen Z
    Sci Transl Med; 2012 Mar; 4(127):127ra38. PubMed ID: 22461642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.
    Zhou GB; Kang H; Wang L; Gao L; Liu P; Xie J; Zhang FX; Weng XQ; Shen ZX; Chen J; Gu LJ; Yan M; Zhang DE; Chen SJ; Wang ZY; Chen Z
    Blood; 2007 Apr; 109(8):3441-50. PubMed ID: 17197433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation.
    Dai HP; Xue YQ; Zhou JW; Li AP; Wu YF; Pan JL; Wang Y; Zhang J
    Genes Chromosomes Cancer; 2009 Dec; 48(12):1027-36. PubMed ID: 19760607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
    Wichmann C; Grez M; Lausen J
    Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.
    Tonks A; Pearn L; Musson M; Gilkes A; Mills KI; Burnett AK; Darley RL
    Leukemia; 2007 Dec; 21(12):2495-505. PubMed ID: 17898786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation.
    Duque-Afonso J; Solari L; Essig A; Berg T; Pahl HL; Lübbert M
    Br J Haematol; 2011 Jun; 153(5):612-22. PubMed ID: 21488857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
    Zhang Y; Wang J; Wheat J; Chen X; Jin S; Sadrzadeh H; Fathi AT; Peterson RT; Kung AL; Sweetser DA; Yeh JR
    Blood; 2013 Jun; 121(24):4906-16. PubMed ID: 23645839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.
    Zaidi SK; Dowdy CR; van Wijnen AJ; Lian JB; Raza A; Stein JL; Croce CM; Stein GS
    Cancer Res; 2009 Nov; 69(21):8249-55. PubMed ID: 19826043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.
    Cao J; Feng H; Ding NN; Wu QY; Chen C; Niu MS; Chen W; Qiu TT; Zhu HH; Xu KL
    Cancer Med; 2016 Nov; 5(11):3205-3213. PubMed ID: 27709797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.